Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vera Therapeutics, Inc. - Class A Common Stock (NQ:VERA)

22.70 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vera Therapeutics, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
(VERA) - Analyzing Vera Therapeutics's Short Interest
Via Benzinga
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
Recap: Vera Therapeutics Q3 Earnings
Via Benzinga
Analyst Highlights 'Rock Solid' Data For Vera Therapeutics' Kidney Disease-Targeted Atacicept, Upgrades To Strong Buy
72-week data from Vera Therapeutics' Phase 2b ORIGIN trial on atacicept for IgA nephropathy. Analysts upgrade stock to Strong Buy, citing impressive efficacy and low-risk profile. 
Via Benzinga
What's Going On With Vera Therapeutics Stock Today?
Vera Therapeutics' significant market movements! Discover the latest on atacicept in IgA nephropathy trials, analyst ratings, and FDA approvals. 
Via Benzinga
Exposures Product Safety
Why Intel Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Intel Corporation (NASDAQ: INTC) fell sharply during Friday’s session. Intel reported upbeat results for its fourth quarter, but issued a weak forecast for the first quarter. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Donald Trump Has Re-Entered The Chat)
The Benzinga Stock Whisper Index provides a look at five stocks that saw increased attention from traders over the past week. 
Via Benzinga
Topics Government
Exposures Political
Booz Allen Hamilton Posts Upbeat Results, Joins AppFolio, Gentex And Other Big Stocks Moving Higher On Friday
U.S. stocks traded mixed, with the Dow Jones gaining around 80 points on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Nasdaq Edges Lower; American Airlines Posts Upbeat Earnings
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning lower on Thursday. The Dow traded up 0.25% to 37,900.45 while the NASDAQ fell 0.13% to 15,462.53. The S&P 500 also... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance. 
Via Benzinga
Why Is Immunology Disease Focused Vera Therapeutics Stock Trading Higher Today?
Vera Therapeutics' 72-week data from Phase 2b ORIGIN trial on atacicept for IgA nephropathy. Sustained reductions in Gd-IgA1, hematuria, and UPCR, with stable eGFR. 
Via Benzinga
Alaska Air Posts Upbeat Earnings, Joins Xerox, United Rentals And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining around 50 points on Thursday. Shares of Alaska Air Group, Inc. (NYSE: ALK) rose during Thursday’s session following upbeat earnings. 
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Rises 2%; Tesla Shares Plunge After Downbeat Results
U.S. stocks traded slightly higher midway through trading, with the Nasdaq Composite gaining around 0.2% on Thursday. The Dow traded up 0.06% to 37,829.32 while the NASDAQ rose 0.22% to 15,515.62. The... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
From Vera Therapeutics
Via GlobeNewswire
Why Vera Therapeutics Stock Soared by 22% This Week
Executive changes and a bullish analyst take combined to boost sentiment on the company. 
Via The Motley Fool
Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Vera Therapeutics
Via GlobeNewswire
Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug
The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy... 
Via Benzinga
Exposures Product Safety
Vera Therapeutics' Kidney Disease Drug Has Opportunity In A Competitive Development Landscape: Analyst
Raymond James initiated coverage on Vera Therapeutics Inc (NASDAQ: VERA), a late-stage drug developer in the autoimmune kidney space. The lead asset, atacicept, is a BLyS/APRIL dual inhibitor fusion... 
Via Benzinga
This Promising Small-Cap Biotech Stock Could Rise 70%, According to Wall Street
Is the stock's risk worth the potential reward? 
Via The Motley Fool
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Synaptics To Rally Over 41%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Scheduled to Present at November Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.